Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Med.

Sec. Dermatology

Pemphigus foliaceus transforming to pemphigus vulgaris: A case report

Provisionally accepted
Mandlin  AlmousaMandlin Almousa1,2,3,4*Navya  KuchibhotlaNavya Kuchibhotla1,2,3Lama  AlabdulaalyLama Alabdulaaly1,5,6,7Marcus  CoueyMarcus Couey8Vikki  NoonanVikki Noonan9Herve  SroussiHerve Sroussi1,2,3
  • 1Department of Oral Medicine, Infection and Immunity, School of Dental Medicine, Harvard University, Boston, United States
  • 2Dana-Farber Cancer Institute, Boston, United States
  • 3Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA., Boston, United States
  • 4Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
  • 5Maxillofacial Surgery and Diagnostic Sciences Department, College of Dentistry, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Riyadh, Saudi Arabia
  • 6Dental Services Department, Ministry of the National Guard Health Affairs, Riyadh, Saudi Arabia., Riyadh, Saudi Arabia
  • 7King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Riyadh, Saudi Arabia
  • 8Department of Oral and Maxillofacial Surgery, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, USA., Boston, United States
  • 9Division of Oral Pathology, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, USA., Boston, United States

The final, formatted version of the article will be published soon.

Pemphigus represents a family of acantholytic autoimmune vesiculobullous diseases. It is classified into multiple subtypes, the two most common of which are pemphigus vulgaris and pemphigus foliaceus. The transition between these two subtypes is uncommon. In this report, we discuss a unique case of biopsy-proven pemphigus foliaceus transitioning to pemphigus vulgaris.

Keywords: Pemphigus Vulgaris, Pemphigus foliaceous, transformation, Vesiculobullous, corticosteroids, rituximab

Received: 18 Sep 2025; Accepted: 25 Nov 2025.

Copyright: © 2025 Almousa, Kuchibhotla, Alabdulaaly, Couey, Noonan and Sroussi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mandlin Almousa

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.